Pharmaresearch Bio Co (XKRX:217950) FCF Margin % : 16.54% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharmaresearch Bio Co's Free Cash Flow for the six months ended in Dec. 2023 was ₩3,313 Mil. Pharmaresearch Bio Co's Revenue for the six months ended in Dec. 2023 was ₩20,031 Mil. Therefore, Pharmaresearch Bio Co's FCF Margin % for the quarter that ended in Dec. 2023 was 16.54%.

As of today, Pharmaresearch Bio Co's current FCF Yield % is 2.89%.

The historical rank and industry rank for Pharmaresearch Bio Co's FCF Margin % or its related term are showing as below:

XKRX:217950' s FCF Margin % Range Over the Past 10 Years
Min: -70.23 Med: 16.54 Max: 28.54
Current: 16.54

During the past 6 years, the highest FCF Margin % of Pharmaresearch Bio Co was 28.54%. The lowest was -70.23%. And the median was 16.54%.

XKRX:217950's FCF Margin % is ranked better than
89.99% of 1039 companies
in the Biotechnology industry
Industry Median: -138.52 vs XKRX:217950: 16.54

Pharmaresearch Bio Co FCF Margin % Historical Data

The historical data trend for Pharmaresearch Bio Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co FCF Margin % Chart

Pharmaresearch Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-70.23

10.18

28.54

24.78

16.54

Pharmaresearch Bio Co Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
FCF Margin %	Get a 7-Day Free Trial			-70.23	10.18	28.54	24.78	16.54

Competitive Comparison of Pharmaresearch Bio Co's FCF Margin %

For the Biotechnology subindustry, Pharmaresearch Bio Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaresearch Bio Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaresearch Bio Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pharmaresearch Bio Co's FCF Margin % falls into.

Pharmaresearch Bio Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pharmaresearch Bio Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	3312.558	/	20030.641
	=	16.54 %

Pharmaresearch Bio Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	3312.558	/	20030.641
	=	16.54 %

Pharmaresearch Bio Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494

Website

http://www.pr-bio.co.kr

Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines